# Safety and Efficacy of P-188 NF in DMD Patients

> **NCT03558958** · PHASE2 · TERMINATED · sponsor: **Phrixus Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** P-188 NF

## Key facts

- **NCT ID:** NCT03558958
- **Lead sponsor:** Phrixus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-08-08
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Terminated due to lack of funding.
- **Last updated:** 2023-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03558958

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03558958, "Safety and Efficacy of P-188 NF in DMD Patients". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT03558958. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*